Drug Profile
Imatinib - Novartis
Alternative Names: CGP 57148; CGP 57148B; CTI 571; Gleevec; Glivec; Imatinib mesilate; Imatinib mesylate; QTI 571; Ruvise; STI 571Latest Information Update: 19 Jan 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Dana-Farber Cancer Institute; Novartis; University of Texas M. D. Anderson Cancer Center
- Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic mastocytosis
- Phase II Acral lentiginous melanoma; Acute myeloid leukaemia; Fibroma; Malignant melanoma; Non-Hodgkin's lymphoma; Prostate cancer
- No development reported Mesothelioma
- Discontinued Diffuse scleroderma; Glioblastoma; Non-small cell lung cancer; Polycythaemia vera; Pulmonary arterial hypertension; Sarcoma; Small cell lung cancer; Systemic scleroderma
Most Recent Events
- 10 Dec 2022 Efficacy and adverse events data from a phase II ASC4MORE trial in Chronic myeloid leukaemia presented at 64th American Society of Hematology Annual Meeting and Exposition 2022 (ASH-Hem-2022)
- 11 Nov 2021 Novartis in collaboration with Asan Medical Center completes a phase Ib/II clinical trial in Gastrointestinal stromal tumours (Second-line therapy or greater, Metastatic disease, Combination therapy, Inoperable/Unresectable) in South Korea (IV) (NCT03609424)
- 06 Apr 2021 Phase-II clinical trials in Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Taiwan, Spain, Spain, Russia, South Korea, France, Canada, Italy, Denmark, Poland, Poland, Germany, United Kingdom, Portugal, Austria (PO) before April 2021 (NCT03578367)